智通财经网·2026-02-25 08:41Core Viewpoint - Citigroup has initiated a 90-day positive catalyst observation for Kanglong Chemical (03759), primarily driven by the upcoming full-year performance announcement and accelerated order growth, leading to a more optimistic guidance for the current year [1] Group 1: Company Performance - Citigroup maintains a "Buy" rating on Kanglong Chemical's H-shares with a target price of HKD 45 [1] - The company is recognized as a global leader in drug research and development, benefiting from the growth trend in China's CRO industry [1] Group 2: Business Expansion - Kanglong Chemical is not only maintaining its leadership in drug research but is also expanding into downstream late-stage clinical development and commercial production, including the biopharmaceutical sector [1] - The company is expected to serve as a leading indicator for the recovery in client demand, providing clearer guidance for future revenue growth [1] Group 3: Financial Projections - Citigroup's earnings per share forecast for the company this year is 4% higher than the market consensus, suggesting potential for upward revision of the current year's guidance above market expectations [1]